Anika Therapeutics (ANIK) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$0.22.
- Anika Therapeutics' EPS (Weighted Average and Diluted) rose 8916.26% to -$0.22 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 6505.14%. This contributed to the annual value of -$3.83 for FY2024, which is 3209.22% up from last year.
- Per Anika Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.22 for Q3 2025, which was up 8916.26% from -$0.33 recorded in Q2 2025.
- Anika Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.45 during Q2 2021, with a 5-year trough of -$4.3 in Q4 2023.
- For the 5-year period, Anika Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.59, with its median value being -$0.31 (2024).
- In the last 5 years, Anika Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 18333.33% in 2021 and then plummeted by 116470.59% in 2023.
- Quarter analysis of 5 years shows Anika Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.4 in 2021, then increased by 15.0% to -$0.34 in 2022, then crashed by 1164.71% to -$4.3 in 2023, then soared by 65.35% to -$1.49 in 2024, then surged by 85.23% to -$0.22 in 2025.
- Its last three reported values are -$0.22 in Q3 2025, -$0.33 for Q2 2025, and -$0.34 during Q1 2025.